Reverse Translational Medicine (RTM™) describes Neurimmune’s approach to drug discovery - learning from populations of humans with a unique capacity to successfully fight a severe disease. In cases of such success being based on antibody responses, Neurimmune identifies genes of antibody candidates which later on need to prove their efficiency in vitro or in vivo model systems. For example Neurimmune has identified antibodies as candidates for therapeutic Alzheimer drugs which are capable of lowering pathological amyloid plaques and restore proper memory function in model systems for Alzheimer’s disease.
Neurimmune’s approach to antibody drug discovery provides a number of unique advantages that result in a superior risk profile compared to traditional antibody drug discovery approaches:
Speed to IND: Through the application of RTM™, Neurimmune identifies panels of human antibodies that have been engineered by nature and do not require further optimization.
Speed to clinical proof of concept: RTM™ identifies those human antibodies that display an excellent safety and efficacy profile thereby significantly increasing the probability of successfully reaching clinical proof of concept.
Neurimmune continues to extend and apply its RTM™ technology platform to identify prime therapeutic antibody candidates. These drugs shall be advanced by the company to the stage where a significant partnership can be formed with biopharmaceutical companies that bring complimentary resources and capabilities to its development and commercialization.